Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Issued: 2019-2024

Historic Shares Issued for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Dec 2024 value amounting to $15.3 million.

  • 4D Molecular Therapeutics' Shares Issued was N/A to -$300.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.3 million, marking a year-over-year change of. This contributed to the annual value of $15.3 million for FY2024, which is 88.16% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Shares Issued of $15.3 million as of FY2024, which was down 88.16% from $129.2 million recorded in FY2023.
  • 4D Molecular Therapeutics' Shares Issued's 5-year high stood at $205.7 million during FY2020, with a 5-year trough of $15.3 million in FY2024.
  • In the last 2 years, 4D Molecular Therapeutics' Shares Issued had a median value of $72.3 million in 2023 and averaged $72.3 million.
  • In the last 5 years, 4D Molecular Therapeutics' Shares Issued skyrocketed by 9,199.91% in 2020 and then crashed by 88.16% in 2024.
  • 4D Molecular Therapeutics' Shares Issued (Yearly) stood at $205.7 million in 2020, then slumped by 44.42% to $114.3 million in 2021, then reached $129.2 million in 2023, then plummeted by 88.16% to $15.3 million in 2024.